查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947852

RNAi疗法市场分析及预测（至2035年）：依类型、产品类型、技术、应用、最终使用者、製程、实施类型及功能划分

RNAi Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 336 Pages | 商品交期: 3-5个工作天内

价格
简介目录

RNAi疗法市场预计将从2024年的26亿美元成长到2034年的81亿美元，复合年增长率约为10%。 RNAi疗法市场涵盖利用RNA干扰技术抑制特定基因表现的治疗方法，可望实现精准医疗。这种创新方法针对遗传性和复杂疾病，推动了药物研发的进步。对遗传通路更深入的了解以及生物技术领域投资的不断增加正在推动市场成长，凸显了个人化医疗解决方案和新型药物递送系统的重要性。

由于基因静默技术的进步和治疗应用范围的不断扩大，RNAi疗法市场正经历强劲增长。目前，肿瘤治疗领域成长最为迅猛，这主要得益于对标靶癌症治疗的需求以及RNAi在治疗传统上难以治疗的标靶方面的巨大潜力。紧随其后的是遗传性疾病领域，该领域因其透过精准医疗为罕见疾病和遗传性疾病提供解决方案的潜力而备受关注。在该领域，小干扰RNA（siRNA）疗法凭藉其在临床试验中已证实的有效性和安全性而主导。微型RNA（miRNA）疗法能够同时调控基因表现，从而带来广泛的治疗益处，已成为成长第二快的领域。策略联盟和对RNAi技术平台不断增长的投资进一步推动了市场发展，预示着该领域具有巨大的创新和扩张潜力。

市场区隔
类型 siRNA、miRNA、shRNA
产品 治疗方法、试剂和耗材
科技 奈米颗粒递送、脂质体递送、病毒递送
应用领域 肿瘤学、心血管疾病、神经退化性疾病、感染疾病、遗传性疾病
最终用户 製药公司、生技公司、研究机构
过程 药物发现、临床开发、非临床试验
部署 体内、体外、体外
功能 基因静默，基因调控

RNAi疗法市场正经历动态变化，策略定价和创新产品发布推动着市场份额的成长。各公司正利用先进的RNA干扰技术推出新型疗法，以满足尚未满足的医疗需求。注重成本效益和治疗效果是竞争优势的关键。此市场环境的特点是产品平臺丰富，并呈现出向个人化医疗和标靶治疗显着发展的趋势。合作与伙伴关係塑造了市场发展轨迹，增强了研发能力并加速了产品开发。竞争标竿分析表明，主要参与者不断创新以保持其竞争优势。监管影响至关重要，北美和欧洲严格的监管准则影响市场准入和扩大策略。法规环境促进了安全性和有效性框架的建立，从而推动了合规性和创新。市场分析强调了策略联盟和监管合规的重要性，认为它们是实现永续成长和市场渗透的关键因素。

主要趋势和驱动因素：

受基因研究进展和慢性病发病率上升的推动，RNAi疗法市场正经历强劲成长。关键趋势包括开发标靶治疗，其精准度更高，副作用更少，优于传统治疗方法。这种精准医疗方法正日益受到重视，与个人化医疗解决方案的广泛普及相契合。 RNA递送系统的新兴技术正在提升RNAi疗法的疗效和安全性。这项进步对于克服稳定性和递送效率的传统挑战至关重要。随着各国政府认识到RNAi疗法在满足未被满足的医疗需求方面的潜力，监管支持和有利政策进一步推动了市场扩张。生物技术公司与研究机构之间的策略联盟和伙伴关係正在促进创新并加速产品开发。此外，生物技术和製药领域研发投入的增加为相关人员探索新的治疗应用提供了沃土。人们对RNAi潜力的认识不断提高，鼓励更多相关人员投资于这个充满前景的领域，为未来的突破铺路。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • siRNA
    • 微型RNA
    • shRNA
  • 市场规模及预测：依产品划分
    • 治疗药物
    • 试剂
    • 消耗品
  • 市场规模及预测：依技术划分
    • 基于奈米颗粒的药物递送
    • 基于脂质的递送
    • 病毒载体递送
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 循环系统
    • 神经退化性疾病
    • 感染疾病
    • 遗传性疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
  • 市场规模及预测：依製程划分
    • 药物发现
    • 临床开发
    • 临床前试验
  • 市场规模及预测：依发展状况
    • In vivo
    • 体外
    • Ex Vivo
  • 市场规模及预测：依功能划分
    • 基因静默
    • 基因调控

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Benitec Biopharma
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • Marina Biotech
  • Calando Pharmaceuticals
  • Sirnaomics
  • Genevant Sciences
  • Oli X Pharmaceuticals
  • Silenseed
  • Atalanta Therapeutics
  • Mi NA Therapeutics
  • Stemirna Therapeutics
  • Phio Pharmaceuticals
  • Sterna Biologicals
  • Gradalis

第九章：关于我们

简介目录
Product Code: GIS10510

RNAi Therapeutics Market is anticipated to expand from $2.6 billion in 2024 to $8.1 billion by 2034, growing at a CAGR of approximately 10%. The RNAi Therapeutics Market encompasses treatments utilizing RNA interference to silence specific gene expressions, offering potential for precision medicine. This innovative approach targets genetic disorders and complex diseases, driving advancements in drug development. Increasing understanding of genetic pathways and rising investments in biotech propel market growth, emphasizing personalized healthcare solutions and novel delivery systems.

The RNAi Therapeutics Market is experiencing robust growth, propelled by advancements in gene-silencing technologies and increasing therapeutic applications. The oncology segment is currently the top-performing sector, driven by the need for targeted cancer treatments and the promise of RNAi in addressing previously undruggable targets. Following closely is the genetic disorders segment, which is gaining traction due to its potential to provide solutions for rare and inherited diseases through precision medicine. Within these segments, small interfering RNA (siRNA) therapeutics lead, owing to their established efficacy and safety profiles in clinical trials. The microRNA (miRNA) therapeutics sub-segment is emerging as the second-highest performer, with its ability to modulate multiple gene expressions simultaneously, offering a broad therapeutic impact. The market is further bolstered by strategic collaborations and increasing investments in RNAi technology platforms, indicating a promising future for innovation and expansion in this domain.

Market Segmentation
TypesiRNA, miRNA, shRNA
ProductTherapeutics, Reagents, Consumables
TechnologyNanoparticle Delivery, Lipid-based Delivery, Viral Delivery
ApplicationOncology, Cardiovascular, Neurodegenerative Disorders, Infectious Diseases, Genetic Disorders
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes
ProcessDrug Discovery, Clinical Development, Preclinical Studies
DeploymentIn Vivo, In Vitro, Ex Vivo
FunctionalityGene Silencing, Gene Regulation

The RNAi Therapeutics Market is witnessing a dynamic shift with a growing market share attributed to strategic pricing and innovative product launches. Companies are leveraging advanced RNA interference technologies to introduce novel therapeutics, catering to unmet medical needs. The strategic emphasis on cost-effectiveness and therapeutic efficacy is driving competitive positioning. This landscape is marked by a robust pipeline of products, indicating a significant trend towards personalized medicine and targeted therapies. The market's trajectory is shaped by collaborations and partnerships that enhance research capabilities and expedite product development. Competition benchmarking reveals a landscape dominated by key players who are continuously innovating to maintain a competitive edge. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe impacting market entry and expansion strategies. The regulatory environment fosters a framework for safety and efficacy, driving compliance and innovation. The market analysis underscores the importance of strategic alliances and regulatory navigation as critical factors for sustained growth and market penetration.

Geographical Overview:

The RNAi Therapeutics Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by substantial investments in research and development. The region's advanced healthcare infrastructure and strong focus on biotechnology innovation further bolster market expansion. Europe follows closely, with a strong emphasis on regulatory support and collaborations between academic institutions and biotech companies. The Asia Pacific region is emerging rapidly, fueled by increasing healthcare expenditure and rising prevalence of chronic diseases. Countries like China and India are becoming key players, with significant investments in RNAi research. These nations are focusing on developing cost-effective therapies to cater to their large populations. Latin America and the Middle East & Africa are gradually gaining traction in the RNAi Therapeutics Market. Brazil and South Africa are spearheading efforts in these regions, with increasing government support and growing interest from international biotech firms.

The RNAi Therapeutics Market is intricately influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, escalating trade tensions necessitate strategic shifts towards enhancing domestic biotech capabilities and reducing dependency on foreign raw materials. China's focus on self-reliance is accelerating its investment in biotech innovation and localized manufacturing. Taiwan, while a pivotal player in biotech supplies, navigates geopolitical vulnerabilities amid US-China strains. Globally, the parent market exhibits robust growth, driven by advancements in genetic medicine, yet faces challenges from protectionist policies and supply chain disruptions. By 2035, market evolution will hinge on strategic alliances and supply chain resilience. Middle East conflicts further compound risks by influencing global energy prices, impacting operational costs and supply chain stability.

Key Trends and Drivers:

The RNAi therapeutics market is experiencing robust growth, driven by advancements in genetic research and the increasing prevalence of chronic diseases. Key trends include the development of targeted therapies that offer precision and reduced side effects compared to traditional treatments. This precision medicine approach is gaining traction as it aligns with the broader shift towards personalized healthcare solutions. Emerging technologies in RNA delivery systems are enhancing the efficacy and safety profiles of RNAi therapeutics. This progress is crucial for overcoming previous challenges related to stability and delivery efficiency. Regulatory support and favorable policies are further propelling market expansion, as governments recognize the potential of RNAi therapies to address unmet medical needs. Strategic collaborations and partnerships between biotech firms and research institutions are fostering innovation and accelerating product development. Additionally, the growing investment in biotechnology and pharmaceutical R&D is providing a fertile ground for market players to explore new therapeutic applications. The increasing awareness of RNAi's potential is encouraging more stakeholders to invest in this promising field, paving the way for future breakthroughs.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 siRNA
    • 4.1.2 miRNA
    • 4.1.3 shRNA
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutics
    • 4.2.2 Reagents
    • 4.2.3 Consumables
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Nanoparticle Delivery
    • 4.3.2 Lipid-based Delivery
    • 4.3.3 Viral Delivery
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Cardiovascular
    • 4.4.3 Neurodegenerative Disorders
    • 4.4.4 Infectious Diseases
    • 4.4.5 Genetic Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Pharmaceutical Companies
    • 4.5.2 Biotechnology Companies
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Clinical Development
    • 4.6.3 Preclinical Studies
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 In Vivo
    • 4.7.2 In Vitro
    • 4.7.3 Ex Vivo
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Gene Silencing
    • 4.8.2 Gene Regulation

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arrowhead Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Silence Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Dicerna Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Arcturus Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Benitec Biopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Quark Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 RXi Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Marina Biotech
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Calando Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sirnaomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genevant Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Oli X Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Silenseed
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Atalanta Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Mi NA Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stemirna Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Phio Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Sterna Biologicals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Gradalis
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us